SH3YL1 and urinary bladder carcinoma: Our analysis of SH3YL1 expression in blood and urine samples of bladder cancer patients receiving cisplatin therapy revealed no significant changes post-treatment, suggesting that SH3YL1 may not serve as a universal marker for cisplatin-induced AKI in this cohort.